Eltrombopag: More Than Just a Thrombopoietin Receptor Agonist (TPO-RA) in Immune Thrombocytopenia (ITP)
نویسندگان
چکیده
منابع مشابه
Eltrombopag--an oral thrombopoietin agonist.
The therapy for immune thrombocytopenic purpura (ITP) has evolved in the recent past. In certain cases therapy for ITP remains inadequate. Thrombopoietin receptor agonists are the latest addition to the armamentarium to manage the thrombocytopenia. While romiplostim was the first second generation thrombopoietin agonist to become available, eltrombopag is particularly attractive as it is an ora...
متن کاملUse of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia
Most children with immune thrombocytopenia (ITP) will have spontaneous remission regardless of therapy, while about 20% will go on to have chronic ITP. In those children with chronic ITP who need treatment, standard therapies for acute ITP may have adverse effects that complicate their long-term use. Thus, alternative treatment options are needed for children with chronic ITP. Thrombopoietin re...
متن کاملChronic immune thrombocytopenia in a child responding only to thrombopoietin receptor agonist.
Immune thrombocytopenia (ITP) is an acquired hematological disease in which the body produces antibodies against its own platelets leading to platelet destruction resulting in isolated thrombocytopenia. Childhood ITP may enter complete remission in the majority of cases within six months from diagnosis. However, 20-30% of affected children may develop chronic ITP (lasting for more than 12 month...
متن کاملA randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia.
Stimulation of platelet production by thrombopoietin-receptor agonists (TPO-RAs) is an effective second-line treatment in immune thrombocytopenia (ITP). This 28-day phase 2 study assigned subjects with ITP of ≥3 months to once-daily oral avatrombopag (2.5, 5, 10, or 20 mg), an investigational nonpeptide TPO-RA active in humans, or placebo; subjects completing randomized treatment could enroll i...
متن کاملTitle: Semi-Physiological Population PK/PD Modeling of Eltrombopag in Healthy Volunteers and Patients with Idiopathic Thrombocytopenic Purpura
Background: Eltrombopag is an orally bioavailable small molecule agonist of thrombopoietin receptor (TPO-R) that has been recently approved in the USA for treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP). The population pharmacokinetics of eltrombopag in healthy volunteers and patients with ITP has been previously described [1]. The model identified health status (healthy...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2019
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood-2019-122848